Human primary cells used to generate organoid models of appendiceal and colorectal cancer
2020
Wake Forest School of Medicine, Winston-Salem, USA
Conducting prospective randomized clinical trials for the treatment of peritoneal malignancies has been historically challenging. Growing evidence support the use of patient-derived tumor organoids (PTO) as a therapeutic response prediction platform. In the present study, the researchers aimed at reconstructing appendiceal and colorectal cancer patient’s tumor in the forms of patient-specific organoids. Tumor tissues were obtained from biopsies of 23 patients, dissociated and the obtained cells were processed to form organoids in vitro. The organoids were then subject to hyperthermic intraperitoneal chemotherapy (HIPEC, the standard of care for these types of cancer) perfusion regimens with varying drug types, drug doses, and temperatures. The capacity of the tested treatment regimens to kill the patient-specific organoid was assessed in vitro using cell viability assays. The model indeed showed a variety of relevant responses depending on the treatment conditions. The study shows proof of principle for utilizing patient-derived organoids as a platform to identify the most efficacious intraperitoneal chemotherapy perfusion protocol in a personalized approach.
Personalized identification of optimal HIPEC perfusion protocol in patient-derived tumor organoid platform
Konstantinos I. Votanopoulos
Added on: 12-21-2021
[1] https://link.springer.com/article/10.1245%2Fs10434-020-08790-2
